AIM
AIM ImmunoTech Inc.Company Information
- Company Name
- AIM ImmunoTech Inc.
- CIK
- CIK0000946644
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AIM: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- AIM
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-17
- Last sale
- 2024-12-19
- Shares purchased (TTM)
- 62,900
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,023,237
- Shares outstanding
- 17,118,695
- Ownership
- 5.98%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -10.34%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 10 | 6 | 3 | 2 | 0 | 1 | 2 | 1 | 4 | 3 | 5 | 15 | ||||||
| Marketable Securities Current | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 7 | 8 | 8 | 7 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 10 | 6 | 3 | 3 | 1 | 3 | 4 | 8 | 10 | 11 | 15 | 23 | ||||||
| Other Receivables Net Current | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | 0 | - | - | - | - | - | - | - | 1 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finite Lived Intangible Assets Net | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | ||||||
| Assets | 13 | 9 | 6 | 5 | 4 | 6 | 9 | 14 | 16 | 16 | 19 | 28 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 0 | 1 | 2 | 1 | 7 | 7 | 6 | 6 | 5 | 7 | 6 | 3 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 5 | 6 | 6 | 4 | 10 | 10 | 10 | 10 | 9 | 10 | 9 | 5 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | 0 | 0 | 1 | - | - | ||||||
| Notes Payable | - | 0 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities Noncurrent | - | - | 8 | 7 | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 5 | 6 | 16 | 12 | 11 | 10 | 10 | 11 | 10 | 11 | 9 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 455 | 446 | 431 | 431 | 427 | 427 | 426 | 424 | 423 | 419 | 419 | 419 | ||||||
| Stockholders Equity | 8 | 2 | -10 | -6 | -7 | -4 | -1 | 3 | 6 | 5 | 10 | 23 | ||||||
| Retained Earnings Accumulated Deficit | -448 | -444 | -441 | -437 | -433 | -431 | -427 | -421 | -417 | -415 | -410 | -397 | ||||||
| Liabilities And Stockholders Equity | 13 | 9 | 6 | 5 | 4 | 6 | 9 | 14 | 16 | 16 | 19 | 28 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 29 | 8 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Shares Outstanding | 29 | 8 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAIM ImmunoTech Inc. (AIM) — SEC Financial Statements & Analysis
AIM ImmunoTech Inc. (AIM) is a biological products, (no diagnostic substances) company, incorporated in DE. AIM ImmunoTech Inc. trades on NYSE as: AIM. AIM ImmunoTech Inc. (AIM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, AIM ImmunoTech Inc. carries a market cap of $4.79M, a P/E ratio of -0.34x, a P/B ratio of 0.62x, a P/S ratio of 50.46x, an enterprise value of $-1.49M, and an EV/EBITDA multiple of 0.14x. On profitability, it posts a gross margin of 1297.89%, an operating margin of -11724.21%, a net margin of -15021.05%, a Return on Equity (ROE) of -2382.30%, a Return on Assets (ROA) of -169.28%, and a Return on Invested Capital (ROIC) of -462.46%. Per share, it reports EPS of $-0.83, diluted EPS of $-0.83, free cash flow per share of $-0.85, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -21.49% year-over-year, net income growth of -11.73% year-over-year, and EPS growth of -96.08% year-over-year. On the balance sheet, it maintains a current ratio of 2.11x, a quick ratio of 2.01x, working capital of $5.49M, a debt-to-equity ratio of 0.64x, a debt ratio of 0.39, an interest coverage ratio of -9.79x, free cash flow of $-14.62M (TTM), and net debt of $-6.28M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.79M
- P/E TTM
- -0.34x
- EPS TTM
- $-0.83
- P/B TTM
- 0.62x
- ROE TTM
- -2382.30%
- ROA TTM
- -169.28%
- Debt To Equity
- 0.64x
- Free Cash Flow TTM
- $-14.62M
- Net Revenue TTM Growth 1Y
- -21.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AIM ImmunoTech Inc. in?
AIM ImmunoTech Inc. (AIM) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does AIM trade on?
AIM ImmunoTech Inc. (AIM) trades on the NYSE.
Where is AIM ImmunoTech Inc. incorporated?
AIM ImmunoTech Inc. is incorporated in DE.
When was AIM ImmunoTech Inc. (AIM)'s most recent SEC filing?
AIM ImmunoTech Inc. (AIM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is AIM's market cap?
AIM ImmunoTech Inc. (AIM) has a market capitalization of $4.79M as of 2026-06-30.
What is AIM's EPS (earnings per share)?
AIM ImmunoTech Inc. (AIM)'s trailing twelve month EPS is $-0.83 as of 2026-06-30.
What is AIM's ROE (return on equity)?
AIM ImmunoTech Inc. (AIM)'s trailing twelve month Return on Equity (ROE) is -2382.30% as of 2026-06-30.
What is AIM's ROA (return on assets)?
AIM ImmunoTech Inc. (AIM)'s trailing twelve month Return on Assets (ROA) is -169.28% as of 2026-06-30.
What is AIM's ROIC (return on invested capital)?
AIM ImmunoTech Inc. (AIM)'s trailing twelve month Return on Invested Capital (ROIC) is -462.46% as of 2024-09-30.
What is AIM's EV/EBITDA?
AIM ImmunoTech Inc. (AIM)'s trailing twelve month EV/EBITDA is 0.14x as of 2026-06-30.